Vir Biotechnology CEO Marianne De Backer sells 72,559 shares in open-market transaction worth $664,350

Vir Biotechnology, Inc. President and CEO Marianne De Backer sold 72,559 shares of the company in an open-market transaction on April 6, 2026, according to an SEC Form 4 filing.

Transaction details

• Shares sold (direct): 72,559
• Transaction value: $664,350
• Post-transaction shares (direct): 948,145
• Post-transaction value (direct ownership): $8.59 million

The transaction value was based on the SEC Form 4 reported sale price of $9.16 per share. The post-transaction value was based on the April 6, 2026 market close price.

Scale and effect on ownership

The sale aligns with De Backer’s recent pattern of open-market selling. The filing notes that the average size of her four most recent open-market sales was approximately 60,000 shares, compared with 72,559 shares sold on April 6.

On a direct basis, the transaction reduced her holdings by 6.76%, leaving her with 948,145 shares directly. She also holds 53,118 shares indirectly through the Ureel-De Backer Family Trust.

Derivatives and options

No derivatives or option exercises were reported. The transaction was exclusively a sale of directly held common stock.

Context: stock performance and trading cadence

Shares were sold at around $9.16 per share. The filing states the stock had appreciated 79.92% over the prior year (as of April 6, 2026). It also characterizes the sale as part of a cadence of periodic sales tied to available share capacity.

Company snapshot

Vir Biotechnology is a commercial-stage biotechnology company focused on immunology-based therapies for serious infectious diseases. Its pipeline includes monoclonal antibodies (including Sotrovimab/Xevudy for COVID-19), RNAi therapeutics for hepatitis B, and investigational therapies for influenza A and HIV.

The company generates revenue through product sales, licensing agreements, and strategic collaborations with major pharmaceutical and research organizations.

As of the market close on 4/10/26, the company reported: price $9.50, market capitalization $1.52 billion, revenue (TTM) $68.56 million, and net income (TTM) -$437.99 million.

What the transaction means for investors

• The insider sale is described as consistent with a CEO supplementing income rather than an exit, with De Backer retaining more than 90% of her holdings.
• While Vir’s sales declined sharply in late 2022 and early 2023, the article notes recent improvement. In February, Vir reported positive phase 1 results for VIR-5500 in patients with advanced-stage prostate cancer, including that 82% of patients in one higher-dose group lowered their PSA levels by at least half.
• Vir also announced a co-development and co-commercialization deal with Astellas Pharma. Under the terms described, Astellas will provide $240 million in cash plus a $75 million equity investment at a premium to Vir’s market price, and Vir will bear 40% of development costs. If approved, Vir would be eligible for a double-digit royalty on international sales, with Astellas leading commercialization in the U.S.